2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van ‘t Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology 2020, 6: 676-684. PMID: 32053137, PMCID: PMC7058271, DOI: 10.1001/jamaoncol.2019.6650.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerPathologic complete responseNeoadjuvant chemotherapyPhase 3 trialResidual cancer burdenStandard neoadjuvant chemotherapyBreast cancerComplete responseInvestigational armStage II/III breast cancerHigher event-free survival rateERBB2-negative breast cancerEvent-free survival rateAnthracycline-based neoadjuvant chemotherapyDistant recurrence-free survivalEnd pointTriple-negative breast cancerCycles of pembrolizumabEffect of pembrolizumabImmune-related endocrinopathiesNeoadjuvant clinical trialsTriple-negative cohortPrimary end pointSecondary end pointsRecurrence-free survival
2006
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006, 107: 1459-1466. PMID: 16948128, DOI: 10.1002/cncr.22177.Peer-Reviewed Original ResearchConceptsResidual tumor sizeBreast conservation therapyNeoadjuvant chemotherapyBreast conservation surgeryBreast cancer patientsTumor sizeConservation therapyBreast conservationConservation surgeryCancer patientsAnthracycline-based neoadjuvant chemotherapyD. Anderson Cancer CenterPaclitaxel neoadjuvant chemotherapyPreoperative chemotherapy regimenPreoperative chemotherapy regimensSuccessful conservative surgeryValidation of nomogramsInstitut Gustave RoussyAnderson Cancer CenterLogistic regression modelsChemotherapy regimenChemotherapy regimensConservative surgeryClinicopathologic dataCancer Center
2005
The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer. Clinical Cancer Research 2005, 11: 8398-8402. PMID: 16322301, DOI: 10.1158/1078-0432.ccr-05-0885.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBcl-2-Associated X ProteinBreast NeoplasmsCell NucleusChemotherapy, AdjuvantCyclophosphamideCytoplasmDoxorubicinFemaleFluorouracilHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingNF-kappa BProto-Oncogene Proteins c-bcl-2Signal TransductionSurvival RateTreatment OutcomeConceptsPathologic complete responseHuman breast cancerNF-kappaBNeoadjuvant chemotherapyComplete responseNeoadjuvant doxorubicinBcl-2Poor responseBreast cancerAnthracycline-based neoadjuvant chemotherapyNF-kappaB.Bcl-2-positive tumorsHuman breast cancer samplesBreast cancer responseClinical outcome dataTranscription factor NF-kappaBBreast cancer pathologistNuclear factor-kappaBBreast cancer samplesPCR ratePositive tumorsChemotherapy responseTumor stainingImmunohistochemical stainingCancer response